<DOC>
	<DOCNO>NCT00956059</DOCNO>
	<brief_summary>The aim clinical trial determine effect security low-dose Prednisone Combined With MMF FK506 Focal Segmental Glomerulosclerosis .</brief_summary>
	<brief_title>Therapeutic Effect Low-dose Prednisone Combined With MMF FK506 Focal Segmental Glomerulosclerosis</brief_title>
	<detailed_description>Focal segmental glomerular sclerosis ( FSGS ) characterize heavy proteinuria nephritic syndrome clinic . The major pathological change scar glomerulus focal segmental . The incidence FSGS increase recent year , unify protocol FSGS treatment provide . Corticosteroid primary drug FSGS treatment clinic . However , corticosteroid treatment low response rate 20 % clinic severe side-effects . The side-effects long-term corticosteroid treatment urge researcher find reliable secure method FSGS treatment . The new immunosuppressant shed light FSGS treatment recently . The usage immunosuppressant FSGS treatment preliminary stage account problem . The main problem include uncertainty curative effect , lack large-scale clinical trial , side-effects long-term application , high recurrence rate withdraw . FSGS immune-induced damage , include abnormality many step humoral immunity cellular immunity . According , design inhibit immune response multi-targets Prednisone Combined With MMF FK506 . Thus dosage drug decrease secure level long-term treatment side-effects control well . Prednisone Combined With MMF FK506 use FSGS treatment effectiveness security .</detailed_description>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Urinary protein≥1.0g/24h Biopsyproved FSGS Age≥16years Understanding content study，signing informed consent form Adherence drug take able longterm follow Sharp deterioration renal function Refractory hypertension Secondary FSGS Serious disease liver，active stage viral hepatitis，or AST、ALT≥2.5 time baseline Serious myelosuppression Being unable longterm follow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>focal segmental glomerulosclerosis</keyword>
	<keyword>prednisone</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>FK506</keyword>
</DOC>